國家衛生研究院 NHRI:Item 3990099045/10642

NHRI > National Institute of Infectious Diseases and Vaccinology > Yee-Chun Chen > Periodical Articles > Item 3990099045/10642

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10642

Title:	Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-gamma autoantibodies in patients with disseminated nontuberculous mycobacterial infection
Other Titles:	Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γ autoantibodies in patients with disseminated nontuberculous mycobacterial infection
Authors:	Wu, UI;Chuang, YC;Sheng, WH;Sun, HY;Jhong, YT;Wang, JY;Chang, SC;Wang, JT;Chen, YC
Contributors:	Division of Infectious Diseases
Abstract:	OBJECTIVE: Anti-interferon-gamma (IFN-gamma) autoantibodies (anti-IFN-gamma Abs) have been increasingly recognized as an important cause of disseminated nontuberculous mycobacterial (DNTM) infection, and identification of this immunodeficiency impacts clinical management. However, the protean disease manifestations and inaccessibility to diagnostic tests in clinical settings hamper its early diagnosis. Here, we sought to determine whether QuantiFERON-TB Gold In-tube (QFT-GIT), a commercialized IFN-gamma release assay, could be used to screen for neutralizing anti-IFN-gamma Abs among previously healthy adults with DNTM infection. METHODS: HIV-uninfected patients with DNTM infection were prospectively enrolled for the QFT-GIT assays. We measured their plasma concentration of anti-IFN-gamma Abs and their neutralizing capacity through enzyme-linked immunosorbent assay and flow cytometry. We then analyzed the correlation between QFT-GIT results and the presence of neutralizing anti-IFN-gamma Abs among patients with and without previously recognized immunosuppression, respectively. RESULTS: Irrespective of the autoantibody concentration or disease activity, all patients with neutralizing anti-IFN-gamma Abs (100%, 30/30) had indeterminate QFT-GIT results due to extremely low or undetectable IFN-gamma levels in the mitogen tubes. None of the four DNTM patients who were previously healthy and tested negative of anti-IFN-gamma Abs had an indeterminate QFT-GIT result, and their IFN-gamma levels in the mitogen tube were significantly higher than those of the patients with anti-IFN-gamma Abs (8.28 IU/mL vs. 0.05 IU/mL, P = 0.001). CONCLUSION: An indeterminate QFT-GIT result due to undetectable or extremely low IFN-gamma level in the mitogen tube suggests the presence of neutralizing anti-IFN-gamma Abs in a previously healthy patient with DNTM infection.
Date:	2018-02
Relation:	Clinical Microbiology and Infection. 2018 Feb;24(2):159-165.
Link to:	http://dx.doi.org/10.1016/j.cmi.2017.06.029
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1198-743x&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000424846600013
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85027467124
Appears in Collections:	[Yee-Chun Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB28694201.pdf		613Kb	Adobe PDF	380	View/Open

Loading...